Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 26, 2004. The report details corporate actions regarding share repurchases and changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share buyback transaction:
- Shares Purchased: 500,000 Ordinary shares.
- Purchase Price: 1,102.85 pence per share.
- Treasury Holdings: 37,868,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,896,261,261 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback executed on August 25, 2004, utilizing authority granted at the Annual General Meeting on May 17, 2004. Additionally, the GSK Trust transferred 2,570 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on August 25, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the execution of the share repurchase and the administrative transfer of shares within the employee trust.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase (500,000 shares x 1,102.85 pence).
- Confirm the impact of the 37,868,000 Treasury shares on earnings per share calculations.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe) hold indirect interests in the GSK Trust shares.
- Confirm that the share buyback was executed within the limits of the shareholder authority granted on May 17, 2004.